Substituted arginines and substituted homoarginines and use ther

Details Substituted arginines and substituted homoarginines and use ther Substituted arginines and substituted homoarginines and use ther

1994-10-24

1995-09-26

Shippen, Michael L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

562560, A61K 31195

Patent

active

054534410

ABSTRACT:
Guanidino substituted arginines or homoarginines based on monoalkyl carbon-substituted ornithines or lysines, having the formula ##STR1## wherein R is (CH.sub.2).sub.y CH.sub.3 or H, R' is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, and R" is CH.sub.2 or C(H)(CH.sub.2).sub.y CH.sub.3, with y ranging from 0 to 5, and x is 0 or 1 and Q is an alkyl group containing from 1 to 6 carbon atoms or NH.sub.2 or NO.sub.2, and only one of R, R' and R" providing an alkyl substituent on the ornithine or lysine moiety. Preferred compounds are .alpha.-methyl-N.sup..omega. -methyl-DL-arginine, RS-.beta.-methyl-N.sup..omega. -methyl-DL-arginine, RS-.gamma.-methyl-N.sup..omega. -methyl-DL-arginine, .alpha.-methyl-N.sup..omega. -amino-DL-arginine, RS-.beta.-methyl-N.sup..omega. -amino-DL-arginine, RS-.gamma.-methyl-N.sup..omega. -amino-DL-arginine, .alpha.-methyl-N.sup..omega. -nitro-DL-arginine, RS-.beta.-methyl-N.sup..omega. -nitro-DL-arginine, and RS-.gamma.-methyl-N.sup..omega. -nitro-DL-arginine. A composition includes said compound together with a pharmaceutically acceptable carrier. Methods of use are directed to delivering said compound to inducible nitric oxide synthase to inhibit the ability of the enzyme to catalyze the conversion of arginine to nitric oxide, to administering said compound to inhibit pathological overproduction of nitric oxide from arginine and to administering said compound to a subject having systemic hypotension due to the pathological overproduction of nitric oxide and an .alpha..sub.1 adrenergic agonist to increase blood pressure in the subject to a clinically acceptable level.

REFERENCES:
patent: 2663668 (1951-12-01), Vrat
patent: 2834713 (1958-05-01), Robbins
patent: 4061542 (1977-12-01), Demny
patent: 4282217 (1981-08-01), Raglioni et al.
patent: 4477428 (1984-10-01), Silberling et al.
patent: 4477429 (1984-10-01), Silberling et al.
patent: 4499067 (1985-02-01), Silberling et al.
patent: 4499068 (1985-02-01), Silberling et al.
patent: 4698442 (1987-10-01), Nestor et al.
patent: 4734438 (1988-03-01), Macri
patent: 5028627 (1991-07-01), Kilbourn et al.
patent: 5059712 (1991-10-01), Griffith
patent: 5132453 (1992-07-01), Griffith
patent: 5216025 (1993-06-01), Gross et al.
patent: 5281627 (1994-01-01), Griffith
patent: 5318992 (1994-06-01), Whitten et al.
Aisaka, K., et al, Biochemical and Biophysic Research Communications, vol. 160, No. 2, pp. 881-886, Apr. 28, 1989.
Iyengar, R., et al, Proc. Natl. Acad. Sci, USA, vol. 84, pp. 6369-6373 Sep. 1987.
Palmer, R. M. J., et al, Nature (London), 333, pp. 664-666, 1988.
Rees, D. D., et al, Proc. Natl. Acad. Sci. USA, vol. 86, pp. 3375-3378, May 1989.
Aisaka, K., Biochemical and Biophysical Research Communications, 163, No. 2, 710-717 (Sep. 1989).
Hibbs, J. B., et al, The Journal of Immunology, 138, No. 2, 550-565 (1987).
Jackson, J. A., et al, J. Pharmacol. Expt. Ther. 209, 271-274 (1979).
Ko, R. Y. C., et al, J. Biomed. Res. 10, 249-258 (1976).
Olanoff, L. S., et al, J. Biomed. Res. 8, 125-136 (1977).
Savoka, K. V., et al, Biochem. Biophys. Acta 578, 47-53 (1979).
Gray, G. A., et al, Br. J. Pharmacol., 103, 1218-1224 (May 1991).
Julou-Schaeffer, G., et al, Am. J. Physiol. 259, H1038-H1043 (Oct. 1990).
Blethen, S. L., et al, J. Biol. Chem., vol. 243, No. 8, 1671-1677 (1968).
Mitchell, J. A., et al, European Journal of Pharmacology, 182, 573-576 (1990).
Olken, N. M., et al, Biochem. Biophys. Res. Comm., vol. 177, No. 2, 828-833 (Jun. 14, 1991).
Stuehr, D. J., et al, Proc. Natl. Acad. Sci. USA, vol. 88, 7773-7777 (Sep. 1991).
Taybor, H., et al (ed.), Methods in Enzymology, vol. XVIIA, pp. 310-317, 335-340, Academic Press, 1970.
Yui, Y., et al, J. Biol. Chem., vol. 266, No. 19, 12544-12547, 1991.
Gross, S. S., et al, Biochemical and Biophysical Research Communications, vol. 170, No. 1, pp. 96-103, Jul. 16, 1990.
Fukuto, J. M., et al, Biochem. Biophys. Res. Commun. 168:458-465 (Apr. 1990).
Fasehun, O. A., et al, J. Pharmacol. Exp. Ther. 255, 1348-1358 (1990).
Greenstein, J. P., et al, Chemistry of Amino Acids, vol. 3, pp. 1850-1853, John Wiley & Sons, Inc., 1961.
Kilbourn, R., et al (1990), in "Nitric Oxide from L-Arginine A Bioregulatory System" (S. Moncada and E. A. Higgs, eds, pp. 61-67, Elsevier Science Publishers, Amsterdam).
Stuehr, D. J. et al, Synthesis of Nitrogen Oxides from L-Arginine by Macrophage Cytosol: Requiement for Inducible and Constitutive Components, Biochem. Biophys. Res. Commun., (1989) vol. 161, 420-426.
Stuehr, D. J. et al., Activated Murine Macrophages Secrete a Metabolite Arginine with the Bioactivity of Endothelium-Derived Relaxing Factor and the Chemical Reactivity of Nitric Oxide, J. Exp. Med., (1989) vol. 169 1011-1020.
Natanson, C. et al., Endotoxin and Tumor Necrosis Factor Challenges in Dogs Simulate the Cardiovascular Profile of Human Septic Shock, Journal of Exp. Med. (1989) 169:823-832.
Schmidt, H. et al., Arginine is a Physiological Precursor of Endothelium Derived Nitric Oxide, Eur. J. of Pharmacology (1988) 154:213-216.
Palmer, R. M. J. et al., L-Arginine is the Physiological Precursor for the Formation of Nitric Oxide in Endothelium-Dependent Relaxation, Biochem. Biophys. Res. Commun. (1988) 153:1251-1256.
Sakuma, I. et al., Identification of Arginine as a Precursor of Endothelium-Derived Relaxing Factor, Proc. Natl. Acad. Sci U.S.A. (1988) 85:8664-8667.
Palmer, R. M. J. et al., Vascular Endothelial Cells Synthesize Nitric Oxide from Arginine, Nature, (1988) vol. 333, 664-666.
Hibbs, J. B. et al., Nitric Oxide: A Cytotoxic Activated Macrophage Effector Molecule, Biochem. Biophys. Res. Commun. (1988) 157:87-94.
Marletta, M. A. et al., Macrophage Oxidation of L-Arginine to Nitrite and Nitrate: Nitric Oxide Is an Intermediate, Biochemistry (1988) 27:8706-8711.
Palmer, R. M. J. et al., Nitric Oxide Release Accounts for the Biological Activity of Endothelium-Derived Relaxing Factor, Nature (1987) 327:524-526.
Stuehr, D. J. et al., Induction of Nitrite/Nitrate Synthesis in Murine Macrophages by BCG Infection, Lymphokines, or Interferon-.gamma., J. of Immunology (1987) 139:518-525.
Iyengar, R. et al., Macrophage Synthesis of Nitrite, Nitrate and N-Nitrosamines: Precursors and Role of the Respiratory Burst, Proc. Natl. Acad. Sci. U.S.A. (1987) vol. 84, 6369-6373.
Turan et al., Acta Chimica Academiae Scientiarum Hungaricae (1975) 85:327-332.
Kilbourn et al., N.sup.G -Methyl-L-Arginine Inhibits Tumor Necrosis Factor-Induced Hypotension: Implications for the Involvement of Nitric Oxide Proc. Natl. Acad. Sci. U.S.A. (1990) 87:3629-3632.
Gross, S. S., et al, Biochem. Biophys. Res. Commun., 178, No. 3, Aug. 15, 1991, 823-829.
Kilbourn, R. G., et al, Journal of the National Cancer Institute, vol. 82, No. 9, May 2, 1990, 772-776.
Kilbourn, R. G., et al, Biochem. Biophys. Res. Commun, 172, No. 3, Nov. 15, 1990, 1132-1138.
Klabunde, R. E., et al, European Journal of Pharmacology, 199:51-59, 1991.
Klabunde, R. E., et al, Biochem. Biophys. Res. Commun., 178, No. 3, Aug. 15, 1991, 1135-1140.
Schmidt, H. H. H. W., et al, Science, vol. 255, Feb. 7, 1992, 721-723.
Kilbourn, R. G., et al, Journal of the National Cancer Institute, 84(11):827-831 (1992).
Lancaster, Jr., J. R., American Scientist, 80:248-257 (1992).
Moncada, S., et al, Eur. J. Clin. Invest. 21, 361-374 (1991).
Moncada, S., et al, J. Cardiovascular Pharm. 17 (suppl.3), S1-S9 (1991).
Moncada, S., et al, Pharmacological Reviews 43(2), 109-142 (1991).
Parratt, J. R., et al, Applied Cardiopulmonary Pathophysiology, 4, 143-149 (1991).
Wang, Q., et al, Life Sciences 49, PL-55-PL-60 (1991).
Vallance, P., et al, Lancet, 28, 997-999 (1989).
Billiar, T. R., et al, Journal of Leukocyte Biology 48:565-569 (1990).
Fostermann, U., et al, Naunyn-Schmiedeberg's Arch. Pharmacol. 340:771-774 (1989).
Gibson, A., et al, British Journal of Pharmacology, Proceedings Supplement, vol. 98, 904P, Dec. 1989.
Lambert, L. L., Life Sciences, vol. 48, pp. 69-75 (1991).
Moore, P. K., et al, British Journal of Pharmacology, Proceedings Supplement, vol. 98, 905P, Dec. 1989.
Mulsch, A., et al, Naunyn-Schmiedberg's Arch. Pharmacol. 341:143-147 (1990).
Nava, E., et al, The Lancet, vo

Affiliated with

Also associated with

Rating

Substituted arginines and substituted homoarginines and use ther does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted arginines and substituted homoarginines and use ther, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted arginines and substituted homoarginines and use ther will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1552075